Navigation Links
FDA approves IND on Lead Product M6G

CAMBRIDGE, England, 26th April 2007 - CeNeS Pharmaceuticals plc (LSE: CEN), the Cambridge based biopharmaceutical company, today announces that the United States Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) application for the clinical development of morphine-6-glucuronide (M6G), its novel drug for the treatment of post-operative pain. Earlier this year, CeNeS announced results of a Phase III study of M6G in Europe in over 500 patients with post-operative pain. The study demonstrated that M6G provided equivalent pain relief to morphine but induced significantly less post-operative nausea and vomiting (PONV). The opening trial under this IND will be a Phase I pharmacokinetic study in volunteers. This study is required by the FDA as is an additional pre-clinical toxicology analysis before progressing to Phase III trials. CeNeS is currently completing the protocol design of the first US Phase III trial. The filing of the IND enhances the package of data already available to potential US partners for review. Neil Clark, Chief Executive of CeNeS, said:

"The FDA's approval of our IND application for M6G is a major landmark in CeNeS' clinical development programme. North America is an attractive market for our drug candidate and M6G is clearly positioned to be a genuine alternative to standard morphine therapy."

For more information please contact: CeNeS Pharmaceuticals plc Neil Clark, CEO Tel: +44 (0)1223 266 466

JM Finn Geoff Nash Tel: +44(0) 207 628 9688

Financial Dynamics Ben Brewerton/Emma Thompson Tel: + 44 (0) 207 831 3113

About CeNeS Pharmaceuticals CeNeS is a biopharmaceutical company specialising in the development and commercialisation of drugs for pain control, sedation and other CNS disorders such as Parkinson's disease. The company is based in Cambridge, England. For further information visit the CeNeS web site: '"/>




Page: 1 2

Related medicine technology :

1. FDA approves MyocondaR IND for MAP in Crohns Disease
2. Pieris Progresses Proprietary Asthma Program: Validation of Pulmonary Delivery of Anticalin-Based Protein Product Candidate
3. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
4. CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and Pain, but Not CRP
5. Publication Confirms that EpCAM, the Target for Two of Micromets Product Candidates, Is Overexpressed on Cancer Stem Cells of Certain Cancers
6. HepaLifes PBS-1 Cells for Influenza Vaccine Production Prove Superior at International Conference
7. Positive Clinical Results for DG041 Lead Product Development Highlights at deCODE R&D Event
8. PromegaExpress Expands Easy Access to Products with New Cabinet
9. Research Documents Scalable Production, Survival Following Engraftment and Positive Impact on Cardiac Function in Infarcted Rats for Gerons Human Embryonic Stem Cell-Based Therapeutic for Heart Failure
10. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
11. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: FDA approves IND Lead Product
(Date:12/1/2008)...d today announced the initiation of a Phase 1/2 cl... JAK2 inhibitor, in leading medical centers in Aus...ibrosis (CIMF). , , The trial is designed ...in patients with CIMF and is expected to enrol up ...l assess the safety profile and evaluate the pharm...
(Date:12/1/2008)...NB-0040 at Children,s Hospital, Health Sciences Ce...wswire/ -- Enobia Pharma, an emerging Canadian bio...ics for serious bone disorders, today announced th...m for hypophosphatasia was dosed. Enobia is invest...0040 for the treatment of this rare and often crip...
(Date:12/1/2008)... , ROCHESTER, Minn., Dec. 1 /PRNewswire-USNew...se of the drug therapy etanercept ineffective in t... of the liver caused by excessive consumption of a...the December issue of Gastroenterology ( http://... Additional audio and video resources, including e...
(Date:12/1/2008)...-FirstCall/ -- Following a,Request for Proposal i...sed,third generation smallpox vaccine, Public Wo...the Canadian Department of National Defence, has a...very of IMVAMUNE(R). , The Canadian authori...ntry,s bio-preparedness programme. , The co...
Breaking Medicine Technology:S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 2S*BIO Advances JAK2 Inhibitor SB1518 into Phase 1/2 Clinical Trial in Australia for the Treatment of Chronic Idiopathic Myelofibrosis 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 2Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 3Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 4Enobia Initiates Infantile Enzyme Replacement Trial for Rare Bone Disease 5Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 2Mayo Clinic Seeks New Therapies for Alcoholic Hepatitis 3The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 2The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Country's Biological Preparedness 3Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone 2324 1Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone 2324 2Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone 2324 3Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone 2324 4Human Genome Sciences to Sponsor Conference Call 2319 1Human Genome Sciences to Sponsor Conference Call 2319 2Tufts researchers update their food guide pyramid for older adults 8590 1Tufts researchers update their food guide pyramid for older adults 8590 2Tufts researchers update their food guide pyramid for older adults 8590 3Entrust Digital Signatures Help Secure More Than 18 Million U S ePassports 1682 1Entrust Digital Signatures Help Secure More Than 18 Million U S ePassports 1682 2Entrust Digital Signatures Help Secure More Than 18 Million U S ePassports 1682 3Entrust Digital Signatures Help Secure More Than 18 Million U S ePassports 1682 4
...URG, Germany, May 10th, 2007 - Antisense,Pharma, a...argeted,therapies for malignant tumors, today anno...12009 in high-grade glioma will be,presented at th...linical Oncology (ASCO), which will be held in Chi...he open-label, randomized dose-finding Phase,IIb-t...
...praisal Committee concludes that alteplase is clin... 14 May 2007 – A new clinical appraisal,publ...nical,Excellence (NICE) in the UK has recommended ... with acute ischaemic stroke, based on,its clinica...tive,care alone.1 Alteplase is marketed as Actilys...
Other Medicine Technology:2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 22007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with,AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion 3Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 2Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 3Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 4Actilyse (alteplase) Recommended by National Institute for Health,and Clinical Excellence for Treatment of Acute Ischaemic Stroke 5
(Date:12/2/2008)...SANTA BARBARA, Calif., Dec. 2 Bio...g products and services, and Alere(R) , who provi..., productivity improvement and complex care manage...trophic conditions to health plans, employers, and... BioIQ,s home-test kits and online reporting tools...
(Date:12/2/2008)...LONDON, Dec. 2 Services form an in...turers, (OEMs,) revenues. It has therefore become,...edical imaging services,market to remain competit...tract penetration rates. , (Logo: http://... New analysis from Frost & Sullivan ( htt...
(Date:12/2/2008)... SPEAK to collect and dis... Bellevue, Wash. (PRWEB) Dece...nnounced the launch of a new initiative to focus p... awareness . The official kick-off of SPEAK will o...Pharmacists (ASHP) 2008 Midyear Clinical Meeting, ...
(Date:12/2/2008)... Xena Health and Solution...l Claims Service "Claims in a Cloud" as ...sgow and London (PRWEB) December 2, 2008 -- Making...s to the launch of the first phase of a "Cl... solution from Corporate Modelling partners Xena ...
Breaking Medicine News(10 mins):Health News:BioIQ and Alere to Provide At-Home Biometric Screening Tests to Employees 2Health News:Encouraging Prospects for Medical Imaging Equipment Services in Europe 2Health News:Encouraging Prospects for Medical Imaging Equipment Services in Europe 3Health News:Pharmacy OneSource Launches SPEAK Initiative to Promote Medication Safety Awareness 2Health News:Corporate Modelling Partners Start Selling BPM in Cloud Service 2
...holesterol can do to people. High-fat diets cause ...re looking at food labels // to know what they con... easier for consumers to avoid trans fats, which p...ked to an increased risk of heart disease, among o...
...e a greater risk of developing Alzheimer’s, the de...stralian researchers // has claimed. The researc...delphia and the Edith Cowan University in Western ...e 'almost certainly' increases risk from Alzheimer...
...y among the people of Queensland when it comes to ...okesman for Queensland Institute of Medical Resear...drive against skin cancer is not having the desire...MR did not elicit the expected number of responses...
...nd are seeking legal protection in the event of a ...n they would be compelled to work // under adverse...ety (OSH) regulations in force in the country are ... sued as per the law. This is very much likely w...
Other Medicine News:Health News:Food labels to include information on trans fats in US 2Health News:Food labels to include information on trans fats in US 3Health News:Obesity could lead to Alzheimer's 2
...iciency and quality to routine urine microscopic a...luorescent flow cytometry with fully automated uri...processing are easily accommodated by the rack-bas... high volume laboratories. Fluorescent flow cytom...
... is a single-use, disposable needle loading device... a Bard BrachyStar needle for interstitial seed im...on safety shield, inner compartment that holds see...lded fitting that connects the cartridge to the ne...
...System uses technology developed by Mortara, the c... digital Holter recorder in 1994. This true 12-lea...r study provides superior ST segment analysis. ,...l recorder allows a full 24-hour 12-lead study to ...
Data review and analysis is carried out with the Acquidata Uromac software already supplied with Acquidata Uromac Lab based urodynamics systems
Medicine Products: